Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Table 1

Baseline demographics and clinical features of the patient populations in this study.

Characteristic	CDDP; ( = 115)	Control; ( = 114)	value
Age (years)	68 ± 6	67 ± 4	0.756
Gender
Male	51	46
Female	64	68
Hypertension ()
Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg	78	82	0.434
Hypercholesterolemia (>200 mg/dL) ()	20	13	0.207
Diabetes mellitus ()	43	37	0.462
BMI (kg/m^2)	24.2 ± 1.6	24.8 ± 1.5	0.633
Cigarette smokers ()	25	14	0.061
Chronic kidney disease ()	2	0	0.159
Clinical presentation
Unstable angina	71	76	0.384
Non-ST-segment elevation myocardial infarction	28	25	0.691
ST-segment elevation myocardial infarction	16	12	0.499
New York Heart Association heart function classification	1.5 ± 1.3	1.8 ± 1.0	0.767
Preprocedural laboratory results
Baseline serum creatinine (M)	80.5 ± 18.7	79.9 ± 27.2	0.975
Baseline creatinine clearance (mL/min)	86.8 ± 28.3	89.2 ± 30.4	0.768